期刊文献+

老年高血脂症强化降脂治疗应用阿托伐他汀和洛伐他汀的效果和安全性分析 被引量:1

Analysis of the Efficacy and Safety of Lipid-lowering Therapy with Atorvastatin and Lovastatin in Elderly Hyperlipidemia Enhancement
下载PDF
导出
摘要 目的探讨分析在老年高血脂症患者强化降脂治疗过程中应用阿托伐他汀和洛伐他汀治疗的临床疗效。方法选取来我门诊部就诊的老年高血脂症患者120例,分为实验组和对照组,对照组患者采用洛伐他汀强化降脂治疗,而实验组采用阿托伐他汀强化降脂治疗,比较两组患者治疗前后LDL-C、HDL-C、TG、TC指标及治疗过程中不良反应发生率。结果治疗后实验组患者的改善程度明显优于对照组。结论对老年高血脂症强化降脂治疗应用阿托伐他汀的临床疗效显著,安全性高,是降脂的首选用药,值得临床推广和使用。 Objective To investigate the clinical efficacy of lipid-lowering therapy to strengthen the analysis applied during atorvastatin and lovastatin therapy in elderly patients with hyperlipidemia. Method Select to elderly patients with hyperlipidemia my clinic for treatment of 120 cases were divided into experimental and control groups, the control group were treated with lovastatin intensive lipid-lowering therapy, while the experimental group atorvastatin intensive lipid-lowering therapy, compare two LDL-C, HDL-C, TG, TC index and the course of treatment incidence of adverse reactions in patients before and after treatment. Results The experimental group was better than control group. Conclusion Elderly hyperlipidemia intensive lipid-lowering therapy applications atorvastatin clinical effects of statins significantly high safety, it is the preferred lipid-lowering medication, and is worthy of clinical use.
出处 《中国医药指南》 2016年第19期15-15,17,共2页 Guide of China Medicine
关键词 老年高血脂 阿托伐他汀他 洛伐他汀 效果 The old patients with hyperlipidemia Atorvastatin Lovastatin Effect
  • 相关文献

参考文献6

二级参考文献61

  • 1李建勇,胡大一,仝其广,史旭波,吴明营,陈捷.中国医师血脂异常防治知识调查[J].中华内科杂志,2005,44(6):461-463. 被引量:23
  • 2陈耀强,李志梁,赵霞.PCI术对冠心病患者hs-CRP及TNFα的影响[J].实用医学杂志,2005,21(21):2430-2431. 被引量:8
  • 3张文斌,宋筱筱,傅国胜,蔡思宇.他汀类药物临床研究进展[J].心血管病学进展,2006,27(1):79-82. 被引量:40
  • 4赵水平.强化降脂治疗的临床应用和意义[J].基础医学与临床,2006,26(2):113-117. 被引量:15
  • 5陆建洪,沈震,汤胜军.阿托伐他汀对缺血性心肌病的心功能影响[J].实用临床医药杂志,2007,11(3):89-90. 被引量:3
  • 6Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cell by anti- atherosclerosis drugs[J]. Circulation, 2001,103 : 2581- 2534.
  • 7Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long term mortality after non ST elevation acute coronary syndrome treated with a very early inva sive strategy in 1042 consecutive patients[J]. Circulation,2006,105:1412-1415.
  • 8Shak PK. Circulating markers of inflammation for vas cular risk prediction: are they ready for prime time? [J]. Circulation,2008. 101 : 1758-1759.
  • 9Yip HK, Wu CJ, Chang HW, et al. l.evels and values of serum high-sensitivity C reactive protein within 6 hours after the onset of acute myocardial infarction[J]. Chest,2007,126:1417-1422.
  • 10Chan DC, WattsGF, Barrett HR, et al, Effect ofator vastatin and fish oil on plasma high sensitivity C reac tive protein concentrations in individuals with visceral o besity[J]. Clinical Chemistry,2002,48(6) : 877 883.

共引文献108

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部